<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311024</url>
  </required_header>
  <id_info>
    <org_study_id>THL/1843/6.02.01/2010</org_study_id>
    <nct_id>NCT01311024</nct_id>
  </id_info>
  <brief_title>Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage</brief_title>
  <acronym>FinIPcarr</acronym>
  <official_title>Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage: a FinIP Effectiveness Trial Satellite Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arto Palmu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute for Health and Welfare, Finland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the indirect effects of a pneumococcal conjugate
      vaccine administered to infants on vaccinees' elder non-vaccinated siblings aged 3 to 7
      years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the indirect effects of a pneumococcal conjugate
      vaccine administered to infants on vaccinees' elder non-vaccinated siblings aged 3 to 7
      years.

      This study includes a cross-sectional sampling of nasopharyngeal and oropharyngeal swabs in
      2011 and a register-based follow-up study for invasive disease, hospital-diagnosed pneumonia,
      tympanostomy tube surgery and outpatient antimicrobial treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Carriage Due to Any Pneumococcal Serotype Included in the Ten-valent Pneumococcal Conjugate Vaccine (PCV10) Vaccine in Older Siblings of Children Vaccinated With Infant Schedules</measure>
    <time_frame>one sampling at 3 to 7 years of age</time_frame>
    <description>Carriage due to any pneumococcal serotype included in the ten-valent pneumococcal conjugate vaccine (PCV10) vaccine in older siblings of children vaccinated with infant schedules. Nasopharyngeal swabs taken once at 3 to 7 years of age when the vaccinated sibling is at least 12 months of age</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Carriage Due to Any Pneumococcal Serotype</measure>
    <time_frame>one sampling at 3 to 7 years of age</time_frame>
    <description>Nasopharyngeal and oropharyngeal swabs taken once at 3 to 7 years of age when the vaccinated sibling is at least 12 months of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carriage Due to Haemophilus Influenzae</measure>
    <time_frame>one sampling at 3 to 7 years of age</time_frame>
    <description>Nasopharyngeal and oropharyngeal swabs taken once at 3 to 7 years of age when the vaccinated sibling is at least 12 months of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive Pneumococcal Disease</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Register follow-up up to 8 years after the vaccination of the younger sibling in the family</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital-diagnosed Pneumonia</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Register follow-up up to 8 years after the vaccination of the younger sibling in the family</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tympanostomy Tube Surgery</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Register follow-up up to 8 years after the vaccination of the younger sibling in the family</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outpatient Antibiotic Treatment</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Register follow-up up to 8 years after the vaccination of the younger sibling in the family</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">2341</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>Sibling vaccinated with PCV GSK1024850A</arm_group_label>
    <description>Older sibling of a child vaccinated with Pneumococcal conjugate vaccine GSK1024850A in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
NOTE: the primary analysis cohort include siblings of the PCV-vaccinated according to infant schedules (excluding siblings of catch-up vaccinated children)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control-vaccinated sibling</arm_group_label>
    <description>Older sibling of a child vaccinated with control vaccine (hepatitis B vaccine or hepatitis A vaccine) in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
NOTE: the primary analysis cohort include siblings of the PCV-vaccinated according to infant schedules (excluding siblings of catch-up vaccinated children)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCV GSK1024850A</intervention_name>
    <description>2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)</description>
    <arm_group_label>Sibling vaccinated with PCV GSK1024850A</arm_group_label>
    <other_name>GSK Biologicals' Synflorix TM vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hepatitis B vaccine or hepatitis A vaccine</intervention_name>
    <description>2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)</description>
    <arm_group_label>Control-vaccinated sibling</arm_group_label>
    <other_name>GSK Biologicals' Engerix TM (hepatitis B) vaccine</other_name>
    <other_name>GSK Biologicals' Havrix TM (hepatitis A) vaccine</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasopharyngeal and oropharyngeal swabs obtained.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Non-PCV-vaccinated 3 to 7 year-old siblings living in the same household with a younger
        child vaccinated in the cluster-randomized Finnish Invasive pneumococcal Disease Trial
        (ClinicalTrials.gov Identifier:NCT00861380)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 3 to 7 years

          -  younger sibling at least 12 months of age living in the same household participates in
             the FinIP or 053 trial (regardless of the vaccination schedule)

          -  at least one parent with fluent Finnish

          -  informed consent from one parent

        Exclusion Criteria:

          -  commercial PCV vaccination administered

          -  study-related PCV vaccination administered (open or blind)

          -  history of antimicrobial treatment within 4 weeks (the child can be enrolled later)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arto A Palmu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute for Health and Welfare, Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute for Health and Welfare</name>
      <address>
        <city>Tampere, Helsinki, Turku, Oulu and Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>http://www.finip.fi</url>
    <description>Public webpage for the FinIP trial and the carriage study</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2011</study_first_submitted>
  <study_first_submitted_qc>March 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2011</study_first_posted>
  <results_first_submitted>April 2, 2014</results_first_submitted>
  <results_first_submitted_qc>April 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2014</results_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Institute for Health and Welfare, Finland</investigator_affiliation>
    <investigator_full_name>Arto Palmu</investigator_full_name>
    <investigator_title>Head of Clinical Research Unit</investigator_title>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>Pneumococcal Vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PCV-vaccinated Sibling (GSK1024850A)</title>
          <description>Older sibling of a child vaccinated with PCV in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
Pneumococcal conjugate vaccine GSK1024850A: 2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380).
Evaluable subjects with NPS sample analysed 482 Siblings of infant-vaccinated children in the PCV 2+1 arm and 445 Siblings of infant-vaccinated children in the PCV 3+1 arm and 568 Siblings of catch-up vaccinated children in the PCV arms 1495 in total</description>
        </group>
        <group group_id="P2">
          <title>Control-vaccinated Sibling</title>
          <description>Older sibling of a child vaccinated with control vaccine (hepatitis B vaccine or hepatitis A vaccine) in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
hepatitis B vaccine or hepatitis A vaccine: 2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
Evaluable subjects with NPS sample analysed 518 Siblings of infant-vaccinated children in the control arms and 271 Siblings of catch-up vaccinated children 789 in total</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1530"/>
                <participants group_id="P2" count="811"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1495"/>
                <participants group_id="P2" count="789"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>These numbers include only the siblings of the infant-vaccinated FinIP children.</population>
      <group_list>
        <group group_id="B1">
          <title>PCV-vaccinated Sibling (GSK1024850A)</title>
          <description>Older sibling of a child vaccinated with PCV in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
Pneumococcal conjugate vaccine GSK1024850A: 2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)</description>
        </group>
        <group group_id="B2">
          <title>Control-vaccinated Sibling</title>
          <description>Older sibling of a child vaccinated with control vaccine (hepatitis B vaccine or hepatitis A vaccine) in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
hepatitis B vaccine or hepatitis A vaccine: 2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="927"/>
            <count group_id="B2" value="518"/>
            <count group_id="B3" value="1445"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" lower_limit="3" upper_limit="7"/>
                    <measurement group_id="B2" value="4" lower_limit="3" upper_limit="7"/>
                    <measurement group_id="B3" value="4" lower_limit="3" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="468"/>
                    <measurement group_id="B2" value="257"/>
                    <measurement group_id="B3" value="725"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="459"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Carriage Due to Any Pneumococcal Serotype Included in the Ten-valent Pneumococcal Conjugate Vaccine (PCV10) Vaccine in Older Siblings of Children Vaccinated With Infant Schedules</title>
        <description>Carriage due to any pneumococcal serotype included in the ten-valent pneumococcal conjugate vaccine (PCV10) vaccine in older siblings of children vaccinated with infant schedules. Nasopharyngeal swabs taken once at 3 to 7 years of age when the vaccinated sibling is at least 12 months of age</description>
        <time_frame>one sampling at 3 to 7 years of age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PCV-vaccinated Sibling (GSK1024850A)</title>
            <description>Older sibling of a child vaccinated with PCV in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
Pneumococcal conjugate vaccine GSK1024850A: 2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380).
Evaluable subjects with NPS sample analysed 482 Siblings of infant-vaccinated children in the PCV 2+1 arm and 445 Siblings of infant-vaccinated children in the PCV 3+1 arm and 568 Siblings of catch-up vaccinated children in the PCV arms 1495 in total</description>
          </group>
          <group group_id="O2">
            <title>Control-vaccinated Sibling</title>
            <description>Older sibling of a child vaccinated with control vaccine (hepatitis B vaccine or hepatitis A vaccine) in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
hepatitis B vaccine or hepatitis A vaccine: 2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
Evaluable subjects with NPS sample analysed 518 Siblings of infant-vaccinated children in the control arms and 271 Siblings of catch-up vaccinated children 789 in total</description>
          </group>
        </group_list>
        <measure>
          <title>Carriage Due to Any Pneumococcal Serotype Included in the Ten-valent Pneumococcal Conjugate Vaccine (PCV10) Vaccine in Older Siblings of Children Vaccinated With Infant Schedules</title>
          <description>Carriage due to any pneumococcal serotype included in the ten-valent pneumococcal conjugate vaccine (PCV10) vaccine in older siblings of children vaccinated with infant schedules. Nasopharyngeal swabs taken once at 3 to 7 years of age when the vaccinated sibling is at least 12 months of age</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="927"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5"/>
                    <measurement group_id="O2" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carriage Due to Any Pneumococcal Serotype</title>
        <description>Nasopharyngeal and oropharyngeal swabs taken once at 3 to 7 years of age when the vaccinated sibling is at least 12 months of age</description>
        <time_frame>one sampling at 3 to 7 years of age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carriage Due to Haemophilus Influenzae</title>
        <description>Nasopharyngeal and oropharyngeal swabs taken once at 3 to 7 years of age when the vaccinated sibling is at least 12 months of age</description>
        <time_frame>one sampling at 3 to 7 years of age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Invasive Pneumococcal Disease</title>
        <description>Register follow-up up to 8 years after the vaccination of the younger sibling in the family</description>
        <time_frame>Up to 8 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital-diagnosed Pneumonia</title>
        <description>Register follow-up up to 8 years after the vaccination of the younger sibling in the family</description>
        <time_frame>Up to 8 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tympanostomy Tube Surgery</title>
        <description>Register follow-up up to 8 years after the vaccination of the younger sibling in the family</description>
        <time_frame>Up to 8 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outpatient Antibiotic Treatment</title>
        <description>Register follow-up up to 8 years after the vaccination of the younger sibling in the family</description>
        <time_frame>Up to 8 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study-related adverse events collected, i.e. those due to NPS and OPS sampling.</time_frame>
      <desc>Note, this study did not include active vaccination of the participants, but indirect impact of the vaccination given to younger siblings was evaluated.</desc>
      <group_list>
        <group group_id="E1">
          <title>PCV-vaccinated Sibling (GSK1024850A)</title>
          <description>Older sibling of a child vaccinated with PCV in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
Pneumococcal conjugate vaccine GSK1024850A: 2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380).
Evaluable subjects with NPS sample analysed 482 Siblings of infant-vaccinated children in the PCV 2+1 arm and 445 Siblings of infant-vaccinated children in the PCV 3+1 arm and 568 Siblings of catch-up vaccinated children in the PCV arms 1495 in total</description>
        </group>
        <group group_id="E2">
          <title>Control-vaccinated Sibling</title>
          <description>Older sibling of a child vaccinated with control vaccine (hepatitis B vaccine or hepatitis A vaccine) in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
hepatitis B vaccine or hepatitis A vaccine: 2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
Evaluable subjects with NPS sample analysed 518 Siblings of infant-vaccinated children in the control arms and 271 Siblings of catch-up vaccinated children 789 in total</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="789"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="789"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Arto Palmu, MD, PhD Research manager,</name_or_title>
      <organization>head of Clinical Research Unit, National Institute for Health and Welfare</organization>
      <phone>+358295247910</phone>
      <email>arto.palmu@thl.fi</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

